RECRUITING

StrokeCog-BBB to Study Cognitive Outcomes Following Stroke

Talk to us

Conditions

Stroke

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this observational study is to learn about cognitive outcomes in stroke patients. The main question it aims to answer are: 1. Is blood-brain barrier permeability compromised for years after stroke, 2. Is a blood biomarker of imbalanced angiogenesis dysregulated in chronic stroke and 3. Are there biomarkers that separately or together predicts cognitive decline after stroke, and are other MRI, blood, and clinical characteristics that are associated. Participants will undergo cognitive testing and MRIs two years apart. Researchers will compare cognitive outcomes in non-stroke patients who have cardiovascular risk factors to understand the effects of stroke on these outcomes.

Official Title

StrokeCog-BBB to Study Cognitive Outcomes Following Stroke

Quick Facts

Study Start:2022-05-17
Study Completion:2027-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06116630

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:45 Years to 90 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Aged 45 years or over
  2. * One or more vascular risk factors (e.g. high blood pressure, diabetes or vascular disease such as angina, a previous heart attack, a heart bypass or peripheral artery disease in the legs)
  3. * Established vascular disease (previous MI, angina, vascular stent in the peripheral bed)
  4. * Sufficiently fluent in written and spoken English
  5. * Living independently in the community
  6. * Willing/able to give consent to study participation.
  1. * Current treatment with IL-1 blockade or established immune-suppressant therapy (e.g. IL-1Ra or IL-1 antibodies), or treatment within the last 3 months
  2. * Currently participating in a clinical trial of investigation medicinal product (CTIMP) or device trial.
  3. * No history of any previous ischaemic or haemorrhagic stroke, a mini-stroke or a serious brain injury
  4. * Do not have dementia
  5. * Renovascular Disease
  6. * Major neurological disease (immune mediated, previous brain tumors)

Contacts and Locations

Study Contact

Muhith Musabbir
CONTACT
650-723-8886
musabbir@stanford.edu

Principal Investigator

Marion Buckwalter, MD
PRINCIPAL_INVESTIGATOR
Stanford University

Study Locations (Sites)

Stanford University Hospital
Palo Alto, California, 94304
United States

Collaborators and Investigators

Sponsor: Stanford University

  • Marion Buckwalter, MD, PRINCIPAL_INVESTIGATOR, Stanford University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-05-17
Study Completion Date2027-12-31

Study Record Updates

Study Start Date2022-05-17
Study Completion Date2027-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Stroke